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Introduction
In 2017, dual energy X-ray absorptiometry (DXA) 
celebrated its 30th anniversary (1). Since the initial 
development of this technique as the successor of dual 
photon absorptiometry, DXA technology assisted to 
continuous technological innovations and is now widely 
considered as the standard of reference in assessing bone 
mineral density (BMD) and fracture risk (1). At the same 
time, technology improvements opened the use of DXA 
to new applications, offering the possibility of evaluating 
several musculoskeletal parameters other than BMD. Body 
composition (BC) measurements have been early available 
after DXA discovery, despite this technique has been 
underutilized compared to BMD measurements (2). This 
paper aims to describe the principle of DXA science, to 
review the technical principles beyond BC measurements, 
and provide a summary of guidelines of clinical applications 
of soft tissue. 
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DXA: technical aspects
The physical principle beyond DXA is that of X-ray 
transmission and attenuation thorough human body at 
two different energy levels (3). Basically, radiation energies 
emitted by DXA machines are variably attenuated based 
on both density and thickness of anatomical structures 
and tissues, as well as the intensity of emitted energy. Two 
aspects should be considered. First, the principle of X-ray 
attenuation relies on the fact that the higher the photon 
energy, the lowest the attenuation. Thus, the X-ray beam 
with lower energy will be more attenuated by tissues, 
with fewer photons passing through. Also, the density of 
material has to be taken in account, as high-density tissues 
(such as bone) attenuate the X-ray beam more than low-
density tissues (such as soft tissues) (4). Based on this, DXA 
produces the so-called R-value, which is the ratio between 
the attenuation coefficients at the two energy levels. 
This difference is specific for each tissue: while R-value 
is constant for bone and fat in all individuals, it varies for 
soft tissue as it depends on the patients’ composition. For 
example, if a subject has a high fat percentage, the R-value 
will be lower compared to a subject with a high lean mass 
percentage (5).
DXA is capable to define the composition of human 
body by discriminating three different compartments, 
based on their specific X-ray attenuation properties: bone 
mineral content (BMC), lipid (triglycerides, phospholipid 
membranes, etc.) which is the so-called “fat mass” (FM), 
and lipid-free soft tissue which is the “lean mass” (LM). Of 
note, lipid-free soft tissue value represents the overall sum 
of overall body water, soft tissue mineral mass, protein, 
etc. (6). Based on this, the evaluation of DXA is typically 
considered a three-compartment model, although this 
technique is not capable to directly estimate all the three 
different components. In fact, about 40–45% of the total 
area of a DXA scan is composed of bone. In this area, DXA 
is only capable to differentiate between bone and the global 
amount of soft tissue, which includes both FM and LM. 
Pixels that are located adjacent to bone, which contain soft 
tissue only, are used to calculate the exact amount of FM 
and LM quantity (3,7).
With regards to the source of X-ray emission, we assisted 
to a technological evolution with the transition from 
pencil-beam densitometers to fan-beam densitometers. 
The characteristic of pencil-beam densitometers is that 
they emit a single rectilinear highly collimated beam of 
X-rays, coupled with a single detector (4). Despite offering 
measurements with higher precision compared to fan-beam, 
these densitometers need longer time to scan the whole-
body surface. On the contrary, fan-beam technology uses a 
fan-shaped beam, which is coupled with multiple detectors, 
allowing shorter scan times with better image resolutions. 
The first fan beam scan was introduced by Hologic in 1993 
with the QDR-2000 densitometer, while the first “narrow” 
fan beam scan was the GE Lunar Prodigy which was 
produced in 2003. Currently, Hologic Inc. (Bedford, MA, 
USA) and GE-Lunar Inc. (Madison, WI, USA) lead the 
market of densitometer manufacturers, both having recently 
introduced new high-resolution machines with several 
technical advancements (iDXA densitometer for GE Lunar, 
Horizon densitometer for Hologic) (7).
In general, the radiation dose of patients performing 
DXA is considered negligible (8). Exposure to ionizing 
radiation is frequently quantified as effective dose, which 
is expressed in sieverts (Sv) and is obtained by combining 
the information about the absorbed doses to the exposed 
tissue/organs and the relative radiation risk assigned to 
these tissue/organs (9). Effective dose is especially useful 
to compare different ionizing radiation sources and with 
natural background radiation. Performing a whole-body 
DXA scan with the last generation of densitometer expose 
patients to about 4–5 μSv, which is even lower than the 
natural background dose (6.7 μSv per day) (3). As an 
example, the effective dose of a computed tomography head 
scan is reported to be around 2 mSv, which is comparable 
to 8-months exposure to natural background radiation (9). 
Radiation dose from DXA depends on different parameters, 
such as tube potential (kVp) and tube current (mA), size 
of the patient, number of images, imaging speed and the 
length of the scan. The operator can control a few of 
these parameters during whole body DXA. With regards 
to contraindications, the International Society of Clinical 
Densitometry (ISCD) considers pregnancy as the only 
relative contraindication to whole body DXA, due to the 
lack of justification to X-ray exposure (10). 
Comparison between DXA and other body 
composition imaging techniques
Currently, magnetic resonance imaging (MRI) and 
computed tomography (CT) are considered the gold 
standard techniques for the assessment of muscle mass/
muscle quantity (11,12). The reason is that both techniques 
are cross-sectional and allow for precise evaluation of 
compartmental BC at different regions of the body (skin, 
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muscle, subcutaneous and visceral adipose tissue) (13). From 
a practical point of view, while DXA values of FM relate to 
the overall “chemical compartment” of triglycerides, CT 
and MRI measures of adipose tissue correspond to a specific 
“anatomical compartment”, which contains adipocytes but 
also other constitutes such as collagenous fibres, fibroblasts, 
capillaries (3). As a consequence, FM measured by DXA is 
somewhat lower than the corresponding values measured by 
cross-sectional imaging. On the other side, LM measured 
by DXA is somewhat higher than that measured by MRI 
and CT, as it includes body proteins together with body 
water, non-fat lipids, carbohydrates, soft tissue minerals (14). 
Nevertheless, there are still several constraints that 
limit the widespread use of CT and MRI in daily routine. 
First of all, both techniques are costly and require 
trained professionals to perform and analyse these 
exams, which typically need specific post-processing (15). 
Other limitations are the compliance of patients, such as 
claustrophobia or subject motion with poor image quality 
(especially for MRI, which also has contraindications), and 
the higher dose of radiation provided by CT with respect to 
DXA (11). More importantly, there is still a lack of evidence 
about the specific cut-off values that should be used for 
defining “low muscle mass” on data provided by CT and 
MRI (16).
On the contrary, DXA is a low-dose radiation technique, 
which is generally reported to be more accessible and 
comfortable for the patients, that can easily provide several 
BC indices in a few minutes. In addition to this, despite 
the above-mentioned differences between DXA and cross-
sectional techniques measurements, several studies have 
found a very good correlation between FM measured by 
DXA and CT/MRI (3). In particular, a study by Chen et al. 
compared DXA-derived measurements of lean mass with 
skeletal muscle mass measured with MRI, showing a 
very high correlation both for the whole body lean mass 
(r=0.94) and leg region (r=0.91) (14). Another study by the 
Japanese group of Midorikawa et al. confirmed these good 
correlations also in the paediatric population of prepubertal 
boys and girls (17). A study form Bredella et al. compared 
CT and DXA, providing similar values of correlation 
in BC measurements (r=0.77–0.95); nevertheless, this 
study warned about the fact that these values are lower in 
markedly obese women, thus DXA may not provide the 
same accuracy in that population (18).
For all these reasons, there is a general consensus about 
the fact that DXA should be considered the technique 
of reference for the assessment in clinical practice of BC 
(16,19,20). More specifically, the revised version of the 
European Working Group on Sarcopenia in Older People 
(EWGSOP) guideline suggests using DXA for detecting 
“low muscle mass” in clinical practice, while considers 
more appropriate the use of CT and MRI in the research 
setting (16).
Performing a whole body DXA scan: practical 
points
The accuracy of LM and FM values produced by DXA 
strictly depends on the multi-step process of whole-body 
scan execution. This multi-step process is composed of 
three parts, each of them of great importance: subject 
preparation, subject positioning, and scan post-processing. 
Figure 1 shows an example of two properly positioned and 
analysed DXA BC scan. 
Proper patient preparation is crucial for maintaining the 
biological variability of LM and FM measurements as low 
as possible. It is well known that BC evaluation is influenced 
by hydration and digestive tract content. Meals have been 
associated with an increase of trunk and whole body lean 
mass values (21). Exercise is another condition that can 
increase LM values at limbs with a decrease of trunk LM, 
due to fluid movement from trunk to periphery (22). Body 
FM seems less affected by meals and exercise, but can vary 
according to the hydration status. In fact, the technology of 
DXA is based on the assumption that the hydration of fat-
free tissue remains constant (at around 73%). Thus, FM 
may vary in cases of severe overhydration due to conditions 
such as ascites or edema, with a percentage that has been 
reported in simulated studies of about 1% when hydration 
changes of 5% (23). As a general rule, the good practice 
would be to measure BC with DXA always in standardized 
conditions in terms of activities, food intake, hour of the 
day. It is reported that the best condition to be reproducible 
is to scan the patient after an overnight fast, so that “real” 
changes can be easily detected (22).
Patient positioning is another critical aspect, as errors in 
this step lead to unavoidable difficulties in the subsequent 
analysis process. The first step is to ensure that subjects 
receiving the DXA remove all external metal that may 
interfere and attenuate the X-ray beam, thus creating 
artifacts. Patients should be positioned in the center of 
the scan with the use of reference lines on the scan table 
(central line and border limit lines). ISCD official positions 
suggest the following method for positioning the patient 
that should be used whenever possible (24,25). The upper 
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Figure 1 Two examples of proper positioned and post-processed whole body DXA scan, according to Hologic manufacturer guidelines. 
The visual comparison of a young man (first two images on the left side) with a middle-aged woman (the last two images on the right side) 
clearly depict differences in fat distribution (represented in yellow), with the woman showing the typical gynoid distribution around the hips 
and thighs. Head line (number 1) is placed below the jaw; pelvis line (number 2) has to be placed just above the iliac crests; two groin lines 
(number 3, in green) have to bisect the femoral neck on each side; trunk lines (number 4, in blue) separate the arm regions from the trunk 
android regions, and they should pass through the gleno-humeral joints along each side of the trunk. A, android region; G, gynoid region; 
VAT, visceral adipose tissue region.
1
4
2
3
A
A
G
G
VAT
limbs should lie along the body, with hands palm down 
without any superimposition with the body. Feet should 
stay in a neutral or slightly internal rotated position, with 
residual space left between the lower limbs. Head should 
be positioned whit chin in neutral position, face up; pillows 
should not be used (6). 
The last step relates to image analysis, which should be 
done according to the manufacturer’s instructions. As a 
general rule, symmetry should be maintained between the 
left and right side when placing regional lines, in order to 
include on both sides the same amount of soft tissue and 
bone. The position of major lines is similar for both GE 
Lunar and Hologic densitometers: the upper horizontal 
line has to be placed just under the jaw, while the pelvis 
horizontal placement is just above the iliac crests. The 
vertical lines on both sides of the trunk should separate arms 
from the chest wall, while the vertical lines in the lower 
limbs have to be placed around the hip/leg. One last vertical 
line should be placed between legs to separate them (4,24). 
See Figure 1 for a detailed explanation of DXA analysis. In 
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Figure 2 Examples of common positioning and postprocessing artifacts that may limit the accuracy of whole body DXA scan. (A,B) Two 
examples of superimposition between fingers and leg fat tissue (see the blue circles). (C) Overweight patients in which positioning may 
result complicated: in this case there is an overall superimposition between several anatomic regions such as fingers with subcutaneous fat 
(blue circle), foots (yellow line) and legs (blue arrow). The latter may create problems in separating the fat mass content between the two 
legs (dashed blue line). (D) Inaccurate placement of pelvis line (green arrow), which is located just above both femoral heads; this create 
problems in the correct identification of android and gynoid regions, which is typically done automatically by the software. (E) Image shows 
the correct placement of the pelvic line (dashed red line), after image correction (indicated by curved arrow).
A
G
G
A
C D
E
A
B
VAT
addition, Figure 2 shows some examples of inaccuracies in 
positioning and analysing a whole body DXA scan.
Can we use DXA for the diagnosis of sarcopenia? 
Current indications
Sarcopenia is a disease typically associated with advancing 
age, characterized by a progressive and generalized loss of 
skeletal muscle mass and strength (13,26-28). The disease 
was typically considered a geriatric syndrome, but it is now 
recognized as an independent disease with its own code 
in the tenth revision of the International Classification 
of Disease (ICD-10-CM, code = M62.84) (29). There is 
increasing awareness of the medical community for this 
condition, as it has been estimated a consistent increase of 
the prevalence of sarcopenia due to advancing age, as well 
as for its association with several negative outcomes such as 
physical disability, falls, hospitalization (30-32). The disease 
is costly to healthcare systems, as it has been shown that the 
cost of care during hospitalization is increased in subject 
with sarcopenia (33).
In 2018, the EWGSOP revised its operational definition 
of sarcopenia, giving primary importance to muscle 
strength as the most important parameter for predicting 
adverse outcomes (16). More practically, according to 
EWGSOP definition, a diagnosis of sarcopenia is probable 
when low muscle strength is detected. The diagnosis is then 
confirmed by the association with low muscle quantity/
quality. When also low physical performance is present, 
the diagnosis of sarcopenia is considered severe (16). Each 
of these parameters can be measured: muscle strength and 
physical performance are typically measured by means of 
different tests such as grip strength, chair stand, gait speed 
or the Short Physical Performance Battery; on the contrary, 
the evaluation of muscle quantity or quality needs the use 
of imaging or non-imaging techniques, such as DXA, MRI, 
CT or Bioelectrical impedance analysis (BIA) (15,34,35).
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Among the different imaging techniques available 
to quantify muscle mass, DXA is currently favoured by 
clinicians and working groups (36). DXA is capable of 
determining regional and total body muscle quantity, 
providing both absolute values of LM as well as LM indices, 
such as the appendicular skeletal muscle mass (ASMM). 
Nevertheless, it has to be taken into account that muscle 
mass correlates to body size. As a consequence, values 
from DXA are typically adjusted to body parameters such 
as height2, weight, or body mass index (BMI) (37). The 
type of adjustment for the specific population is debated, 
but many guidelines suggest now the use of ASMM with 
height2 adjustment (ASMM/height2), which is also known 
as ASMM index (ASMMI) (16,19,24). Several absolute 
thresholds of ALMI have been proposed over time, with the 
most recent update in 2018 by the EWGSOP2 suggesting 
to use the following values as lower cut-off points: ASMMI 
<7.0 kg/m2 for men and ASMMI <6.0 kg/m2 for women 
(11,16). Alternatively, absolute values of ASMM can either 
be used, with the following lower cut-off points: ASMM 
<20 kg for men, ASMM <15 kg for women (16,27).
It is very important to point out that the above-
mentioned values should not be used alone to diagnose 
“sarcopenia”. In fact, such diagnosis needs the concurrent 
presence of low muscle strength detected at functional 
tests. So, it is encouraged to use the term “low muscle 
mass” in DXA reports in case of reduced ASMM/ASMMI 
values (24). In addition to this, the medical community is 
debating about the clinical value of combining the use of 
ASMMI and femoral neck BMD to predict fracture risk, 
similarly to what is commonly performed in the Fracture 
Risk Assessment Tool (FRAX®) (38). To date, literature 
evidence suggests that DXA-derived ASMMI has a limited 
role in the prediction of incident fractures (39). Despite the 
well-known link between bone and muscle, fracture is just 
one outcome resulting from sarcopenia, and ASMMI may 
have better value for identifying other adverse outcomes 
such as falls. In their editorial, Harvey concludes that 
the use of DXA-derived lean mass indices still does not 
provide additional risk information when BMD is also 
considered; further studies are warranted to understand the 
role of possible use of ASMMI in the FRAX. The possible 
introduction of newer DXA based tools for evaluating bone 
strain together with body composition may even provide 
additional information for fracture risk prediction (40).
A possible DXA drawback is related to the fact that 
densitometers of different brands may not give the same 
results (36,41). A practical suggestion is to perform the 
follow-up scan always with the same densitometer, to 
remove such source of variability.
Whole body DXA and adipose indices: how can 
we use them?
Several adipose indices can be obtained with whole body 
DXA, some of them being similar to lean indices. These 
values help in providing additional data about whole body 
and regional FM distribution. Among them we will discuss 
the fat mass index (FMI), the Android/Gynoid (AG) ratio 
and lipodystrophy indices (%fat Trunk/Leg, Trunk/limb fat 
mass ratio).
FMI is calculated as the total body fat mass with height2 
adjustment. The use of FMI has been advocated to diagnose 
obesity, similarly to what done by BMI. The rationale of 
using FMI is based on the assumption that BMI, despite 
its ease of use, is not a direct adiposity measurement 
parameter (25). On the contrary, despite the use of FMI 
(which is a direct measurement of adiposity) has its 
rationale, there is an ongoing debate about what cut-off 
point should be used to better diagnose obesity. Figure 3 
compares BMI thresholds to a list of FMI cut-off points 
proposed for defining obesity categories both for male 
and female subjects using FMI, according to the National 
Health and Nutrition Examination Survey (NHANES) 
reference values (42). Nevertheless, it is still unclear which 
associations exist between such thresholds and obesity 
related negative outcomes. Despite this, FMI has a clear 
advantage over BMI for the evaluation of obesity, as the 
latter does not take into account patients’ lean mass.
Regarding obesity, several studies clearly showed that 
DXA measurements of FM (including FMI) are strongly 
correlated with negative cardiovascular and metabolic 
outcomes, independent of BMI (44,45). A recent study from 
Vasan et al. evaluated the associations between DXA values 
and conventional anthropometry measurements of fat (waist 
and hip circumference), together with cardiovascular disease 
(CVD) risk markers (46). The result of this study confirmed 
that conventional anthropometry underestimated the 
associations of regional adiposity (subcutaneous and visceral 
fat) with diabetes and CVD risk markers. 
Another parameter that can be used for evaluating the 
CVD risk is the AG fat mass ratio, which is analogue to the 
more commonly used anthropomorphic measurement of 
waist-to-hip ratio (47). DXA machines obtain this value as 
the ratio between the android and gynoid region of interest 
(ROI). Android ROI is typically defined as the region 
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Figure 3 Comparison between the values of DXA-based fat mass index (obtained as the ratio between fat mass/height2) and those of body 
mass index in the classifications for obesity categories. Fat mass index categories are obtained from NHANES reference values (42); body 
mass index categories from World Health Organization (WHO) (43).
Gender
Fat mass index (kg/m²)
Normal Overweight Obesity Class I Obesity Class II Obesity Class III
Female subjects 5–9 >9–13 >13–17 >17–21 >21
Male subjects 3–6 >6–9 >9–12 >12–15 >15
Body mass index (kg/m2)
Normal Overweight Obesity Class I Obesity Class II Obesity Class III
Male/female 18.5–24.9 25.0–29.9 30.0–34.9 35.0–39.9 ≥40
between the last thoracic rib and the upper part of iliac 
wings. Gynoid ROI is located below the android ROI, and 
includes the gluteo-femoral region with an upper horizontal 
line placed caudally to the pelvis line, and a lower horizontal 
line identified by measuring twice the height of the android 
ROI (4). It has been shown that an increase in the android 
fat distribution (with values of AG ratio greater than 1) is 
associated with conditions such as dyslipidemia and insulin 
resistance, as well as other cardiovascular risk factors such 
as impaired glucose tolerance, hypercholesterolemia, 
hypertr iglycer idemia,  and hypertension (47-49) . 
Unfortunately, as for FMI, despite the evidence of a strong 
correlation between the increasing amount of android fat 
and CVD risk, there is still no consensus on the possible 
cut-off points to be used for defining a specific high-risk 
patient.
Recent evidence of the possible concurrent presence of 
low BMD (osteopenia or osteoporosis), reduced muscle 
mass (sarcopenia), and increased adiposity (obesity) led the 
scientific community to propose a new term, the so-called 
“osteosarcopenic obesity” (50). As a matter of fact, DXA is 
currently the only technique which is capable of identifying 
all these conditions at the same time, by evaluating the 
presence of low ASMMI together with adipose indices (such 
as FMI) and BMD (with DXA performed at lumbar spine 
and femur). Figure 4 compares two subjects with reduced 
muscle mass according to ASMMI values, but with different 
percentage of fat mass as evaluated with FMI.
The use of trunk/limb FM ratio have been advocated to 
evaluate the fat redistribution in HIV patients treated with 
older regimens of antiretroviral agents, which were at risk 
of complications such as lipodystrophy and lipoatrophy (25). 
In fact, the association of lipodystrophy with agents such 
as zidovudine and stavudine has been extensively reported, 
being confirmed in a systematic review of randomized 
controlled trials (51). Nevertheless, the ISCD Reporting 
guideline of 2013 clearly specified that a consensus about 
the values to be accepted has never been reached (25). 
Recently in 2019 a study by Alikhani et al. evaluated the 
prevalence of lipodystrophy in HIV patients and the 
association to cumulative exposure of newer antiretroviral 
drugs agents (52). In this study, the DXA cut-off point to 
define lipodystrophy was the presence of trunk/limb fat 
ratio ≥1.5. Surprisingly, lipodystrophy resulted still very 
common in HIV infected patients, being correlated with 
the duration of some new antiretroviral drugs such as 
raltegravir. Such results keep open the possibility to still 
use DXA for the evaluation of suspected lipodystrophy, and 
probably suggests additional investigations are required to 
understand the utility of such adipose indices.
Visceral fat assessment with whole body DXA: 
technical aspects
One of the most recent developments for whole body DXA 
is the possibility to evaluate visceral adipose tissue (VAT). 
This can be done with both GE and Hologic densitometers, 
thanks to new software which are called CoreScanTM for 
GE-Lunar and InnerCoreTM for Hologic (4). This software 
firstly estimates the amount of subcutaneous fat (SAT) in 
the android ROI of DXA scan, by detecting the fat located 
on both sides of the abdominal cavity. This estimate of 
SAT is then subtracted from the total FM in the android 
ROI, thus providing the final amount of VAT. Figure 5 
explains the working principle beyond VAT estimation by 
DXA. Measurements of VAT by DXA showed to be highly 
correlated with those obtained by CT (r=0.93) (53). DXA 
VAT measurements have several advantages over CT, first 
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Figure 4 Comparison between two subjects with low appendicular skeletal muscle mass index (ASMMI) values (red arrow) and different 
values of fat mass index (FMI, asterisks). Subject A is a young male with long-standing facioscapulohumeral muscular dystrophy, presenting 
with both reduced ASMMI (5.31 kg/m2, normal values for men >7.0 kg/m2) and very low values of FMI (normal values for men between 3 
and 6 kg/m2), suggesting the concurrent presence of reduced muscle mass and underweight. Subject B is a middle-aged woman with reduced 
muscle mass (ASMMI =5.86 kg/m2, normal values for women >6.0 kg/m2) but with high values of FMI, a condition which may raise the 
suspect for sarcopenic obesity. 
Fat Lean Bone Fat Lean Bone
Measure Result Percentile
YN AM
Total Body % Fat 17.9 13 6
Fat Mass/Height2 (kg/m2) 2.82* 2 1
Android/Gynoid Ratio 0.78
% Fat Trunk/% Fat Legs 0.79 17 8
Trunk/Limb Fat Mass Ratio 0.85 19 10
Est. VAT Mass (g) 169
Est. VAT Volume (cm3) 183
Est. VAT Area (cm2) 35.1
Measure Result Percentile
YN AM
Total Body % Fat 42.2 79 45
Fat Mass/Height2 (kg/m2) 11.1* 69 44
Android/Gynoid Ratio 1.06
% Fat Trunk/% Fat Legs 0.83 61 34
Trunk/Limb Fat Mass Ratio 0.90 68 35
Est. VAT Mass (g) 833
Est. VAT Volume (cm3) 901
Est. VAT Area (cm2) 173
Measure Result Percentile
YN AM
Lean/Height2 (kg/m2) 12.3 1 1
Appen. Lean/Height2 (kg/m2) 5.31 1 1
Measure Result Percentile
YN AM
Lean/Height2 (kg/m2) 14.6 40 42
Appen. Lean/Height2 (kg/m2) 5.86 27 41
Adipose Indices Adipose Indices
Lean Indices Lean Indices
A
A
G G
VAT
VAT
A B
Subject A Subject B
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and foremost related to lower radiation dose provided to 
patients.
The clinical importance of VAT is widely recognized, 
as it has been showed that VAT is a better predictor of 
mortality than SAT or AG ratio (54). Thus, it is possible 
that VAT will replace the AG ratio as a risk factor for the 
assessment of CVD risk with DXA (25). It is important to 
consider that even subjects with normal values of BMI may 
have an increased amount of VAT accumulation, thus being 
at higher risk than that estimated by only conventional 
anthropometry measurements (46).
Regarding thresholds, VAT is typically expressed 
as a real measurement in cm2. Cross-sectional studies 
suggested that VAT levels exceeding 100–110 cm2 were 
associated with adverse metabolic profile in women (55). 
On CT measurements of VAT, Pickhardt et al. found that 
a threshold of 70 cm2 yielded a sensitivity, specificity, and 
accuracy of 83.7%, 80.0%, and 81.3%, respectively, for 
metabolic syndrome in women (56). Another paper suggests 
specific cut-off points of 100 cm2 for considering a subject 
at increased “metabolic risk”, while a VAT higher than 
160 cm2 is associated with high metabolic risk (57).
Conclusions
The analysis of body composition with DXA is becoming 
more and more popular among physicians, as DXA has 
the potentiality to evaluate LM and FM with an accuracy 
that is close to that of CT and MRI, but with some 
advantages compared to cross-sectional techniques. As a 
consequence, whole body DXA is increasingly used for 
different potential applications, such as the investigation of 
low lean mass in the setting of suspected sarcopenia. The 
possible combination of LM and FM values with that of 
BMD obtained with DXA at central site open the possibility 
for a more comprehensive evaluation of osteometabolic 
disorders, such as osteosarcopenia and sarcopenic obesity. 
There is still a lot that has to be done, and further research 
studies are warranted to provide clear cutoff values for 
adipose indices in cardiovascular disease, as well as to 
understand the role of ASMMI in the possible prediction of 
fracture risk in patients with sarcopenia.
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